Group 1 - The company plans to globally offer 94.69 million shares, with 9.47 million shares available in Hong Kong and 85.22 million shares for international sale, along with an over-allotment option of 14.20 million shares [1] - The subscription period is set from December 18 to December 23, with a maximum offer price of HKD 24.05 per share and an entry fee of approximately HKD 12,146.27 for 500 shares [1] - The total expected fundraising amount is HKD 2.277 billion, with a net amount of HKD 2.026 billion, which will be used for further clinical research and development of key pipeline candidates, early drug discovery, generative AI model development, and operational funding [1] Group 2 - The company is expected to be listed on the main board by December 30, 2025, with Morgan Stanley, CICC, and GF Securities serving as joint sponsors [2] - Established in 2014, the company is recognized as a reputable AI-driven biotechnology firm with a global presence [2] - The projected net profits for the fiscal years 2023, 2024, and the first half of 2025 are -USD 212 million, -USD 17.1 million, and -USD 19.2 million, reflecting year-on-year changes of 4.59%, 91.92%, and -339.29% respectively [2]

Group 1 - The company plans to globally offer 94.69 million shares, with 9.47 million shares available in Hong Kong and 85.22 million shares for international sale, along with an over-allotment option of 14.20 million shares [1] - The subscription period is set from December 18 to December 23, with a maximum offer price of HKD 24.05 per share and an entry fee of approximately HKD 12,146.27 for 500 shares [1] - The total expected fundraising amount is HKD 2.277 billion, with a net amount of HKD 2.026 billion, which will be used for further clinical research and development of key pipeline candidates, early drug discovery, generative AI model development, and operational funding [1] Group 2 - The company is expected to be listed on the main board by December 30, 2025, with Morgan Stanley, CICC, and GF Securities as joint sponsors [2] - Established in 2014, the company is recognized as a reputable AI-driven biotechnology firm with a global presence [2] - The net profits for the fiscal years 2023, 2024, and the first half of 2025 are projected to be -$212 million, -$17.096 million, and -$19.215 million respectively, with year-on-year changes of 4.59%, 91.92%, and -339.29% [2]